Abdom Radiol (NY)

1. YANG Y, Gong B, Kong X, Guo Y, et al
   Habitat-based radiomics-clinical analysis for early prediction of bladder cancer recurrence: a retrospective cohort study.
   Abdom Radiol (NY). 2026 Apr 21. doi: 10.1007/s00261-026-05516.
   

   >> Share

   
   

   
   Adv Sci (Weinh)

2. WU J, Ren X, Zhai Z, Wang L, et al
   O-GlcNAcylated TAP1 Impairs Antigen Presentation and Promotes Immune Evasion in Bladder Cancer.
   Adv Sci (Weinh). 2026 Apr 24:e19955. doi: 10.1002/advs.202519955.
   

   >> Share

   
   

   
   Am J Cancer Res

3. ZHANG X, Wang L, Sun W, Yang X, et al
   Therapeutic and prognostic value of repeat transurethral resection for high-grade Ta bladder cancer: a propensity score matching analysis.
   Am J Cancer Res. 2026;16:771-795.
   

   >> Share

   
   
4. LI Q, Bai J, Zheng S, Liao J, et al
   THAP7-AS1 orchestrates IGF2BP3-m(6)A-dependent CCN2 mRNA stabilization to promote lymphatic metastasis in bladder cancer.
   Am J Cancer Res. 2026;16:1215-1230.
   

   >> Share

   
   

   
   Ann Surg Oncol

5. LI C, Cheng C, Li S, Wang D, et al
   ASO Author Reflections: Imaging Tumor Heterogeneity to Reveal Occult Nodal Risk in Bladder Cancer.
   Ann Surg Oncol. 2026 Apr 24. doi: 10.1245/s10434-026-19699.
   

   >> Share

   
   

   
   Anticancer Drugs

6. WANG Y, Yuan J, Guo S, Liu Y, et al
   Ubiquitination mediated cisplatin resistance in bladder cancer.
   Anticancer Drugs. 2026 Mar 2. doi: 10.1097/CAD.0000000000001816.
   

   >> Share

   
   

   
   Biochem Biophys Rep

7. AHMED HU, Hosen MR, Mostofa MA, Hossain MA, et al
   Whole exome sequencing identifies somatically mutated genes in bladder cancer: A pilot study from Bangladesh.
   Biochem Biophys Rep. 2026;46:102574.
   

   >> Share

   
   

   
   Bioorg Chem

8. YU H, Liu D, Xu J, Li A, et al
   Design, synthesis and anti-bladder cancer activity of novel dihydroartemisinin-ibuprofen hybrids.
   Bioorg Chem. 2026;176:109893.
   

   >> Share

   
   

   
   Biosens Bioelectron

9. SUN X, Qian L, Jin D, Guo B, et al
   Bifunctional DNA multivalent structure integrating stable capture of urothelial carcinoma cells with CRISPR/Cas12a signal amplification for bladder cancer detection.
   Biosens Bioelectron. 2026;306:118710.
   

   >> Share

   
   

   
   BJU Int

10. ZHANG B, Wang C, Shang P
    Comment on 'Reducing complexity in International Bladder Cancer Group intermediate-risk non-muscle-invasive bladder cancer stratification: a three-factor approach'.
    BJU Int. 2026 Apr 23. doi: 10.1111/bju.70302.
    

    >> Share

    
    
11. VAN HOOGSTRATEN LMC, Vermeulen SH, Hof JP, van der Heijden AG, et al
    Surveillance patterns in non-muscle-invasive bladder cancer across risk groups: a real-world analysis.
    BJU Int. 2026 Apr 23. doi: 10.1111/bju.70297.
    

    >> Share

    
    

    
    BJUI Compass

12. TITUS RS, Riveros C, Velasquez EL, Nguyen DD, et al
    Addition of immune checkpoint inhibitors to intravesical BCG for high-risk BCG-naive non-muscle invasive bladder cancer: Systematic review and meta-analysis.
    BJUI Compass. 2026;7:e70194.
    

    >> Share

    
    

    
    BMC Med

13. YU EY, Wesselius A, Mehrkanoon S, Goosens M, et al
    Correction: Vegetable intake and the risk of bladder cancer in the BLadder Cancer Epidemiology and Nutritional Determinants (BLEND) international study.
    BMC Med. 2026;24:259.
    

    >> Share

    
    

    
    Cancer Immunol Immunother

14. FURRIEL F, Laranjeira P, Pereira M, Silva S, et al
    CD39/CD73-mediated immunosuppression and tumor aggressiveness in bladder cancer.
    Cancer Immunol Immunother. 2026;75:154.
    

    >> Share

    
    

    
    Cell Rep Med

15. CHEN Z, Peng S, Fu S, Lin S, et al
    Targeting TPX2-dependent lineage plasticity by CDK4/6 inhibition reverses therapy resistance in neuroendocrine bladder carcinoma.
    Cell Rep Med. 2026;7:102712.
    

    >> Share

    
    

    
    Cochrane Database Syst Rev

16. LEE CH, Shepherd A, Sathianathen N, Hwang JE, et al
    Extended versus standard lymph node dissection for urothelial carcinoma of the bladder in people undergoing radical cystectomy.
    Cochrane Database Syst Rev. 2026;4:CD013336.
    

    >> Share

    
    

    
    Discov Oncol

17. ZHANG W, Dai L, Luo M, Shi H, et al
    Overexpression of MFAP4 inhibits the proliferation, migration, and invasion of bladder cancer cells.
    Discov Oncol. 2026 Apr 20. doi: 10.1007/s12672-026-05056.
    

    >> Share

    
    

    
    Eur J Cancer

18. DEVELTERE D, Tsantoulis P, Olivier T
    Censoring patterns and inconsistent results in checkpoint inhibitor and adjuvant BCG trials for high-risk bladder cancer.
    Eur J Cancer. 2026;240:116740.
    

    >> Share

    
    

    
    Eur J Hosp Pharm

19. PIPITONE S, Vitale MG, Baldessari C, Sabbatini R, et al
    Extravasation of enfortumab vedotin: a case report and literature review on antibody-drug conjugates.
    Eur J Hosp Pharm. 2026;33:284-286.
    

    >> Share

    
    

    
    Eur Urol

20. LOBO N, Contieri R, Mertens L, Kamat AM, et al
    Re: Kitamura H, Tsukamoto T, Kakehi Y, et al. Active surveillance versus intravesical bacillus Calmette-Guerin for high-grade T1 bladder cancer with negative second transurethral resection: the randomized noninferiority phase 3 JCOG1019 trial. Eur Uro
    Eur Urol. 2026 Apr 21:S0302-2838(26)02072-5. doi: 10.1016/j.eururo.2026.
    

    >> Share

    
    
21. PICCOLINI A, Paciotti M, Buffi NM
    Re: Kitamura H, Tsukamoto T, Kakehi Y, et al. Active Surveillance Versus Intravesical Bacillus Calmette-Guerin for High-Grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial. Eur Uro
    Eur Urol. 2026 Apr 22:S0302-2838(26)02071-3. doi: 10.1016/j.eururo.2026.
    

    >> Share

    
    
22. D'ANDREA D, Soria F, Gontero P, Shariat SF, et al
    Re: Kitamura H, Tsukamoto T, Kakehi Y, et al. Active Surveillance Versus Intravesical Bacillus Calmette-Guerin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial. Eur Uro
    Eur Urol. 2026 Apr 22:S0302-2838(26)02069-5. doi: 10.1016/j.eururo.2026.
    

    >> Share

    
    

    
    Eur Urol Oncol

23. YOSHIDA K, Oka S, Takefuji Y
    Re: Jurczok N, Dernbach G, Ebner B, et al. Multiregional immune profiling reveals prognostic patterns in bladder cancer. Eur Urol Oncol. In press. http://dx.doi.org/10.1016/j.euo.2025.12.006.
    Eur Urol Oncol. 2026 Apr 22:S2588-9311(26)00095.
    

    >> Share

    
    
24. SUN XS, Boustani J, Sun R
    Deep Systemic Response in Muscle-invasive Bladder Cancer: Is Radical Cystectomy Still Necessary?
    Eur Urol Oncol. 2026 Apr 21:S2588-9311(26)00108.
    

    >> Share

    
    
25. SINGH N, Srivastav M
    Re: Sebastian C. Schmid, Matthias Jahnen, Kilian Schiller, et al. Radiation Therapy Combined with Immunotherapy Before Radical Cystectomy in Locally Advanced Bladder Cancer: A Prospective, Single-arm, Multicenter, Phase 2 Trial (RACE-IT). Eur Urol Onc
    Eur Urol Oncol. 2026 Apr 17:S2588-9311(26)00082.
    

    >> Share

    
    
26. D'ANDREA D, Soria F, Roupret M, Gontero P, et al
    Design and Rationale of the ROGUE-1 Registry: A Multicentric Prospective Registry for Primary T1 Nonmuscle-invasive Bladder Cancer.
    Eur Urol Oncol. 2026 Apr 18:S2588-9311(26)00096.
    

    >> Share

    
    

    
    Eur Urol Open Sci

27. CHOI Y, Cho SW, Hong J, Lee J, et al
    A Novel Radiomics-based Interpretable Model for Bladder Cancer Grade Prediction Using White-Light Cystoscopy Images.
    Eur Urol Open Sci. 2026;87:71-79.
    

    >> Share

    
    
28. CALLEGARIN F, Amodeo A, Claps F, Crestani A, et al
    A Study to Evaluate Efficacy and Safety of Hydeal Cyst Intravesical Instillations in Non-muscle Invasive Bladder Cancer Patients Treated With Intravesical Chemotherapy or Immunotherapy.
    Eur Urol Open Sci. 2026;87:25-30.
    

    >> Share

    
    

    
    Genes Dis

29. PULANCO MC, Zheng XY, Sankin A, Zheng D, et al
    Immune checkpoint B7x promotes immune evasion and resistance to PD-1/PD-L1 blockade in bladder cancer.
    Genes Dis. 2025;13:101950.
    

    >> Share

    
    

    
    Hum Pathol

30. WU DJ, Pacheco R, Chan E, Lowe AC, et al
    Prostatic adenocarcinoma identified on transurethral resection of bladder tumor: A clinicopathologic series of a diagnostically relevant potential pitfall.
    Hum Pathol. 2026;171:106059.
    

    >> Share

    
    
31. LI H, Matoso A
    S100 expression and SDHB status define distinct biological subsets of bladder paraganglioma.
    Hum Pathol. 2026;171:106072.
    

    >> Share

    
    

    
    Immunotargets Ther

32. LIANG HQ, Li YJ, Yu JY, Mo QZ, et al
    Multi-Omics Analysis Reveals m7G Methylation-Related Genes May Be Involved in TGF-beta Signaling-Mediated Anti-PD-L1 Response in Bladder Cancer.
    Immunotargets Ther. 2026;15:583577.
    

    >> Share

    
    

    
    Indian J Med Res

33. DAGDEVIREN MA, Oguzkan SB, Ozaslan M, Erturhan MS, et al
    Expression levels of miRNA 22-5p and miRNA 337-5p in bladder cancer.
    Indian J Med Res. 2026;163:290-294.
    

    >> Share

    
    

    
    Indian J Surg Oncol

34. DEMIRCI A, Uzel T
    Comparative Analysis of Oncological Outcomes between Trimodal Therapy and Radical Cystectomy in Patients with Variant Bladder Cancer.
    Indian J Surg Oncol. 2026;17:721-727.
    

    >> Share

    
    

    
    Int J Biol Sci

35. LI P, Yang E, Zhang X, Shi Y, et al
    TIMP1 Derived from Mesenchymal Stem Cells Promotes Bladder Cancer Progression by Regulating the Formation of VDIMs through the RAP1 Pathway.
    Int J Biol Sci. 2026;22:3322-3341.
    

    >> Share

    
    

    
    Int J Clin Oncol

36. OHTSU A, Otani Y, Arai S, Rogachevskaya A, et al
    Comparative genomic landscape of primary and metastatic bladder urothelial carcinoma in a large-scale cohort.
    Int J Clin Oncol. 2026;31:868-877.
    

    >> Share

    
    
37. MITO O, Muto S, Kitamura K, Nagaya N, et al
    Prevalence and prognostic impact of cancer cachexia in patients with bladder cancer: a multicenter retrospective study.
    Int J Clin Oncol. 2026 Apr 18. doi: 10.1007/s10147-026-03043.
    

    >> Share

    
    

    
    J Mater Chem B

38. JIANG L, Li Y, Liu W, Wu S, et al
    Harmonizing the adhesion-release dilemma: a bio-based injectable hypertonic hydrogel for bladder perfusion therapy.
    J Mater Chem B. 2026;14:4602-4612.
    

    >> Share

    
    

    
    J Med Econ

39. WILLIAMS S, Cho S, Morrison L, Joshi K, et al
    Cost-per-responder analysis of TAR-200 versus other Food and Drug Administration-approved novel and generic treatments among patients with Bacillus Calmette-Guerin-unresponsive, high-risk, non-muscle-invasive bladder cancer with carcinoma in situ in t
    J Med Econ. 2026;29:1198-1212.
    

    >> Share

    
    

    
    J Transl Med

40. XIAO X, Lu X, Peng J, Li L, et al
    ATAD3A promotes bladder cancer progression by regulating glycolysis through MYC stabilization.
    J Transl Med. 2026 Apr 18. doi: 10.1186/s12967-026-08139.
    

    >> Share

    
    

    
    Kathmandu Univ Med J (KUMJ)

41. THAPA BB, Shah AK, Adhikari B, Mishra U, et al
    En Bloc Versus Conventional Resection of Primary Bladder Tumor.
    Kathmandu Univ Med J (KUMJ). 2025;23:307-311.
    

    >> Share

    
    

    
    Minerva Urol Nephrol

42. DI TRAPANI E, Lo Giudice A, Mazzone E, Dell'oglio P, et al
    Detrimental effect of delayed or incomplete BCG protocols administration after trans-urethral tumor resection in patients with non-muscle-invasive bladder cancer: a systematic review.
    Minerva Urol Nephrol. 2026;78:170-176.
    

    >> Share

    
    
43. RESCA S, Morra S, Frego N, Tamburini S, et al
    Evolution of survival outcomes in robot-assisted radical cystectomy over 20 years of experience in a high-volume tertiary robotic center.
    Minerva Urol Nephrol. 2026;78:249-256.
    

    >> Share

    
    

    
    Mol Cancer Ther

44. CAROSINO CM, Olson DJ, Mazahreh RC, Ortiz DJ, et al
    An Integrin beta6-targeted antibody-drug conjugate optimized for intravesical delivery to treat non-muscle invasive bladder cancer.
    Mol Cancer Ther. 2026 Apr 20. doi: 10.1158/1535-7163.MCT-26-0077.
    

    >> Share

    
    

    
    Nat Rev Urol

45. LOBO N, Zuiverloon TCM, Mertens LS
    Worse bladder cancer outcomes in women than in men - bias, biology or both?
    Nat Rev Urol. 2026 Apr 22. doi: 10.1038/s41585-026-01145.
    

    >> Share

    
    

    
    Scand J Urol

46. NUMMI A, Nurminen P, Kesti O, Hogerman M, et al
    Impact of asymptomatic bacteriuria on the outcomes and tolerability of Bacillus Calmette-Guerin immunotherapy.
    Scand J Urol. 2026;61:148-155.
    

    >> Share

    
    

    
    Urol Case Rep

47. ISHIKAWA D, Naiki T, Naiki-Ito A, Suzuki H, et al
    Long-term recurrence-free survival following total penectomy and additional chemotherapy for solitary penile metastasis from muscle invasive bladder cancer.
    Urol Case Rep. 2026;66:103433.
    

    >> Share

    
    
48. SCHIAVONE N, Finati M, Ricapito A, Fanelli A, et al
    Solitary adrenal gland metastasis detected at 24-month follow-up for muscle-invasive bladder cancer.
    Urol Case Rep. 2025;65:103334.
    

    >> Share

    
    

    
    Urol Oncol

49. DA COSTA RMM JR, Pereira do Nascimento LA, Silva TA, Panhoca R, et al
    Comparison between cutaneous ureterostomy and the ileal conduit in patients with urothelial bladder carcinoma undergoing radical cystectomy: Expanding eligibility for the gold standard treatment.
    Urol Oncol. 2026;44:111031.
    

    >> Share

    
    
50. WANG B, Davis L, Nizam A, Moningi S, et al
    Patterns of local therapy following enfortumab vedotin in advanced urothelial carcinoma.
    Urol Oncol. 2026;44:110994.
    

    >> Share

    
    
51. YE J, Li Y, Zhang M, Liao X, et al
    Efficacy of disitamab vedotin-based therapy in HER2-negative and HER2-low locally advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis.
    Urol Oncol. 2026;44:111034.
    

    >> Share

    
    
52. DURSUN F, Akgul B, Gelfond JA, Leach RJ, et al
    Surgical operation duration as a predictor of venous thromboembolism risk after radical cystectomy.
    Urol Oncol. 2026;44:110983.
    

    >> Share

    
    

    
    Urol Pract

53. FILSON CP, Slezak JM, Luong TQ, Aboushwareb T, et al
    Real-World Utility of Cxbladder Triage for Patients with Microhematuria: A Matched Cohort Study.
    Urol Pract. 2026;13:260-266.
    

    >> Share

    
    

    
    World J Urol

54. CESTA G, Zolfanelli C, Lauciello V, Lorusso V, et al
    A molecular landscape tracking the progression of non-muscle invasive bladder cancer.
    World J Urol. 2026;44:320.
    

    >> Share

    
    
55. LONGONI M, Falkenbach F, Marmiroli A, Le QC, et al
    Correction: Development and external validation of a nomogram predicting cancer-specific mortality-free survival after trimodal therapy in muscle-invasive bladder cancer.
    World J Urol. 2026;44:318.
    

    >> Share

    
    
56. AKAND M, Van Weyenbergh T, Moris L, Muilwijk T, et al
    Effectiveness of preoperative chemotherapy and radical cystectomy in clinically node-positive and node-negative bladder cancer patients.
    World J Urol. 2026;44:319.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share